Study of people with primary sclerosing cholangitis in Switzerland
Part of Digestive system clinical trials.
This study follows people diagnosed with primary sclerosing cholangitis to better understand the condition over time. It may help doctors learn which factors affect health and care, and improve future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary sclerosing cholangitis (PSC)
- You can be any age
- You live in Switzerland
- Your diagnosis can be based on standard guidelines or specialist liver-center diagnosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with primary sclerosing cholangitis (PSC) over time to learn more about the condition. It is observational, meaning no new treatments are tested—just regular checkups and data collection to better understand PSC.
This study follows children and young adults with primary sclerosing cholangitis (PSC) to understand the condition and how it shows up on scans or biopsy. It may help doctors better recognize PSC and choose the best next steps for care.
This study collects bile and uses it to grow small lab models (organoids) from people with primary sclerosing cholangitis (PSC) and from people without PSC. Researchers want to better understand how PSC changes bile cells, which could improve future diagnosis or treatments.
This study creates mini-livers (colangioids) from tiny tissue samples to find genetic reasons for atypical primary sclerosing cholangitis (aPSC), a rare liver disease. It aims to help doctors better understand and diagnose the condition.
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
This trial tests a new drug, HK-660S, for people with primary sclerosing cholangitis (PSC), a liver disease that affects the bile ducts. It aims to see if the drug can improve liver health and slow the disease.
Hear when a new Cholangitis, Sclerosing trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.